Table 3.
Radiological characteristics of the target vestibular schwannomas before, during, and after treatment with bevacizumab.
| Radiologic Characteristics | n = | |
|---|---|---|
| First presentation | 16 | |
| Extrameatal extension, n (%) | 13 (81.3) | |
| Extrameatal volume, cm3, median (range) | 2.07 (0.09–24.45) | |
| Start of bevacizumab treatment | 16 | |
| Extrameatal extension, n (%) | 14 (87.5) | |
| Extrameatal volume, cm3, median (range) | 1.24 (0.05–12.67) | |
| Relative change, % (range) | 43 (−61–816) | |
| End of bevacizumab treatment | 16 | |
| Extrameatal extension, n (%) | 13 (81.3) | |
| Extrameatal volume, cm3, median (range) | 1.15 (0.0 1–10.52) | |
| Relative change, % (range) | −12 (−100 1–6) | |
| Most recent radiologic surveillance | 12 | |
| Extrameatal extension, n (%) | 11 (91.7) | |
| Extrameatal volume, cm3, median (range) | 1.52 (0.03–8.25) | |
| Relative change, % (range) | 27 (−22–275) | |
1 Full regression of extracanicular tumor component. Legend: n = number of patients, max. = maximum, cm = centimeters.